Compare Stocks

Date Range: 

 Eagle PharmaceuticalsOrganiGramRelmada TherapeuticsKalVista PharmaceuticalsAnaptysBio
SymbolNASDAQ:EGRXNASDAQ:OGINASDAQ:RLMDNASDAQ:KALVNASDAQ:ANAB
Price Information
Current Price$41.65$2.75$36.34$25.22$26.16
52 Week RangeN/AHoldBuyBuyHold
MarketRank™
Overall Score1.01.61.11.81.5
Analysis Score0.04.23.34.53.2
Community Score2.93.01.43.02.8
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.81.71.7
Earnings & Valuation Score0.60.60.00.00.0
Analyst Ratings
Consensus RecommendationN/AHoldBuyBuyHold
Consensus Price TargetN/A$4.41$57.50$50.17$35.80
% Upside from Price TargetN/A60.41% upside58.23% upside98.92% upside36.85% upside
Trade Information
Market Cap$546.41 million$820.14 million$608.59 million$613.05 million$715.97 million
Beta0.740.30.532.130.15
Average Volume117,34121,071,02169,727856,890485,047
Sales & Book Value
Annual Revenue$195.89 million$64.61 millionN/A$12.69 million$8 million
Price / Sales2.7912.69N/A48.3189.50
Cashflow$1.52 per share$0.03 per shareN/AN/AN/A
Price / Cash27.49101.50N/AN/AN/A
Book Value$13.11 per share$1.04 per share$7.88 per share$4.69 per share$14.93 per share
Price / Book3.182.64N/A5.381.75
Profitability
Net Income$14.31 million$-101,290,000.00N/A$-29,120,000.00$-97,340,000.00
EPS$1.38($0.08)($2.16)($1.64)($3.60)
Trailing P/E Ratio119.00N/AN/AN/AN/A
Forward P/E Ratio138.83N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins2.65%-207.26%N/A-229.45%N/A
Return on Equity (ROE)8.50%-10.00%-32.03%-47.45%-19.09%
Return on Assets (ROA)5.44%-7.14%-31.41%-41.84%-17.94%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.16%0.17%N/AN/AN/A
Current Ratio3.60%2.66%37.02%7.56%14.13%
Quick Ratio3.45%3.39%37.02%7.56%14.13%
Ownership Information
Institutional Ownership Percentage95.12%10.84%64.31%90.19%N/A
Insider Ownership Percentage21.10%N/A9.30%18.00%13.00%
Miscellaneous
Employees106619145694
Shares Outstanding13.12 million298.23 million16.75 million24.31 million27.37 million
Next Earnings Date5/10/2021 (Confirmed)7/20/2021 (Estimated)5/12/2021 (Confirmed)7/7/2021 (Estimated)8/9/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Analyst Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - NasdaqAnalyst Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - Nasdaq
nasdaq.com - May 9 at 9:41 AM
Forecast: Analysts Think AnaptysBio, Inc.s (NASDAQ:ANAB) Business Prospects Have Improved DrasticallyForecast: Analysts Think AnaptysBio, Inc.'s (NASDAQ:ANAB) Business Prospects Have Improved Drastically
finance.yahoo.com - May 9 at 9:41 AM
Q3 2021 EPS Estimates for AnaptysBio, Inc. (NASDAQ:ANAB) Lowered by AnalystQ3 2021 EPS Estimates for AnaptysBio, Inc. (NASDAQ:ANAB) Lowered by Analyst
americanbankingnews.com - May 7 at 8:27 AM
AnaptysBio, Inc. (NASDAQ:ANAB) to Post Q2 2021 Earnings of $0.01 Per Share, Wedbush ForecastsAnaptysBio, Inc. (NASDAQ:ANAB) to Post Q2 2021 Earnings of $0.01 Per Share, Wedbush Forecasts
americanbankingnews.com - May 6 at 8:04 AM
AnaptysBio (NASDAQ:ANAB) Announces Quarterly  Earnings Results, Beats Estimates By $0.03 EPSAnaptysBio (NASDAQ:ANAB) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS
americanbankingnews.com - May 5 at 4:08 PM
AnaptysBio (NASDAQ:ANAB) Shares Gap Up to $23.50AnaptysBio (NASDAQ:ANAB) Shares Gap Up to $23.50
americanbankingnews.com - May 5 at 12:02 PM
Antibody Library Technology Market (2020-2027): Regional outlook, components, and end- users segments are expected to be most attractive segments over the forecast year |AnaptysBio Inc, MorphoSys AG, XOMA Corporation - Good News GumAntibody Library Technology Market (2020-2027): Regional outlook, components, and end- users segments are expected to be most attractive segments over the forecast year |AnaptysBio Inc, MorphoSys AG, XOMA Corporation - Good News Gum
goodnewsgum.com - May 5 at 8:48 AM
AnaptysBio EPS beats by $0.03, beats on revenue - Seeking AlphaAnaptysBio EPS beats by $0.03, beats on revenue - Seeking Alpha
seekingalpha.com - May 5 at 12:40 AM
AnaptysBio Drug Trial Result Disclosures Draw Shareholder Suit - Bloomberg LawAnaptysBio Drug Trial Result Disclosures Draw Shareholder Suit - Bloomberg Law
news.bloomberglaw.com - May 4 at 7:39 PM
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates - NasdaqAnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
nasdaq.com - May 4 at 7:39 PM
Anaptysbio Q1 Loss Per Share $0.66 - CMLViz.com - CML NewsAnaptysbio Q1 Loss Per Share $0.66 - CMLViz.com - CML News
cmlviz.com - May 4 at 7:39 PM
AnaptysBio Announces First Quarter 2021 Financial Results - GlobeNewswireAnaptysBio Announces First Quarter 2021 Financial Results - GlobeNewswire
globenewswire.com - May 4 at 7:39 PM
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline UpdatesAnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
finance.yahoo.com - May 4 at 7:39 PM
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue EstimatesAnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 4 at 7:39 PM
AnaptysBio (NASDAQ:ANAB) Shares Gap Down to $23.68AnaptysBio (NASDAQ:ANAB) Shares Gap Down to $23.68
americanbankingnews.com - May 4 at 11:06 AM
Last Weeks Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More - BenzingaLast Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More - Benzinga
benzinga.com - May 2 at 9:36 AM
AnaptysBio - BenzingaAnaptysBio - Benzinga
benzinga.com - May 2 at 9:36 AM
Novavax Inc. stock falls Friday, still outperforms market - MarketWatchNovavax Inc. stock falls Friday, still outperforms market - MarketWatch
marketwatch.com - April 30 at 7:53 PM
Should You Sell AnaptysBio Inc (ANAB) Stock Friday? - InvestorsObserverShould You Sell AnaptysBio Inc (ANAB) Stock Friday? - InvestorsObserver
investorsobserver.com - April 30 at 7:53 PM
AnaptysBio (NASDAQ:ANAB)  Shares Down 5.3% AnaptysBio (NASDAQ:ANAB) Shares Down 5.3%
americanbankingnews.com - April 30 at 11:58 AM
Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline - Yahoo FinanceEarnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline - Yahoo Finance
finance.yahoo.com - April 28 at 2:05 PM
Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to DeclineEarnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline
finance.yahoo.com - April 28 at 2:05 PM
AnaptysBio (NASDAQ:ANAB) Shares Gap Up  Following Insider Buying ActivityAnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Insider Buying Activity
americanbankingnews.com - April 28 at 10:34 AM
Insider Buying: AnaptysBio, Inc. (NASDAQ:ANAB) Director Purchases 13,900 Shares of StockInsider Buying: AnaptysBio, Inc. (NASDAQ:ANAB) Director Purchases 13,900 Shares of Stock
americanbankingnews.com - April 27 at 7:38 PM
Ecor1 Capital, Llc Buys 99,600 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockEcor1 Capital, Llc Buys 99,600 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock
americanbankingnews.com - April 27 at 7:38 PM
DateCompanyBrokerageAction
4/20/2020Eagle PharmaceuticalsCantor FitzgeraldReiterated Rating
3/25/2020Eagle PharmaceuticalsRoyal Bank of CanadaReiterated Rating
4/24/2019Eagle PharmaceuticalsMizuhoReiterated Rating
10/31/2018Eagle PharmaceuticalsPiper Jaffray CompaniesDowngrade
4/20/2021OrganiGramCIBCReiterated Rating
4/15/2021OrganiGramStifel NicolausBoost Price Target
4/14/2021OrganiGramRaymond JamesLower Price Target
4/14/2021OrganiGramCanaccord GenuityBoost Price Target
4/13/2021OrganiGramAlliance Global PartnersLower Price Target
4/8/2021OrganiGramBMO Capital MarketsUpgrade
8/10/2020OrganiGramJefferies Financial GroupReiterated Rating
3/17/2021Relmada TherapeuticsOppenheimerReiterated Rating
10/28/2020Relmada TherapeuticsThe Goldman Sachs GroupDowngrade
5/4/2020Relmada TherapeuticsSunTrust BanksInitiated Coverage
1/10/2020Relmada TherapeuticsSVB LeerinkReiterated Rating
12/16/2019Relmada TherapeuticsGuggenheimInitiated Coverage
2/25/2021KalVista PharmaceuticalsRoth CapitalBoost Price Target
2/10/2021KalVista PharmaceuticalsHC WainwrightBoost Price Target
1/26/2021KalVista PharmaceuticalsNeedham & Company LLCBoost Price Target
3/22/2021AnaptysBioTruist SecuritiesUpgrade
3/15/2021AnaptysBioWedbushReiterated Rating
3/8/2021AnaptysBioJPMorgan Chase & Co.Downgrade
5/7/2020AnaptysBioCredit Suisse GroupBoost Price Target
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.